Skip to main content

Table 1 Effect of bosentan on blood pressure, exercise capacity and blood oxygen saturation

From: Long-term results of treatment with bosentan in adult Eisenmenger’s syndrome patients with Down’s syndrome related to congenital heart disease

Parameter, mean ± SD (p value)

Baseline

Month 3

Month 6

Month 9b

Month 12

Month 18

Month 24

Final follow-upa

SBP (mmHg)

125.7 ± 14.0

105.0 ± 11.8b (0.063)

111.7 ± 9.8b (0.125)

111.7 ± 5.2b (0.094)

114.3 ± 13.7 (0.250)

113.7 ± 9.6 (0.188)

106.4 ± 7.5 (0.063)

108.6 ± 9.0 (0.094)

DBP (mmHg)

80.0 ± 5.8

74.2 ± 8.6b (0.125)

79.2 ± 8.0b (1.000)

73.3 ± 11.7b (0.281)

69.3 ± 8.4 (0.031)

73.6 ± 8.5 (0.250)

68.9 ± 7.8 (0.063)

68.6 ± 4.8 (0.031)

6MWD (m)

199.6 ± 69.1

291.7 ± 73.1b (0.063)

260.7 ± 60.2b (0.063)

292.3 ± 112.7b (0.031)

301.6 ± 88.7 (0.016)

317.4 ± 105.8 (0.016)

291.9 ± 115.4 (0.016)

303.7 ± 99.9 (0.016)

SaO2 (%) at rest

81.7 ± 6.6

87.2 ± 5.6b (0.063)

88.4 ± 2.7 (0.031)

89.3 ± 2.5b (0.031)

89.0 ± 2.5 (0.016)

87.9 ± 4.5 (0.109)

89.3 ± 1.8 (0.031)

88.3 ± 3.2 (0.016)

SpO2 (%) before 6MWT

81.0 ± 6.6

87.0 ± 6.4b (0.094)

87.2 ± 3.8b (0.031)

89.3 ± 1.0b (0.031)

88.7 ± 3.1 (0.031)

88.6 ± 5.3 (0.047)

89.9 ± 1.8 (0.016)

88.0 ± 3.3 (0.016)

SpO2 (%) at end of 6MWT

61.6 ± 7.6

68.2 ± 9.3b (0.250)

67.7 ± 3.0b (0.063)

72.5 ± 6.2b (0.031)

70.6 ± 10.1 (0.078)

71.0 ± 7.5 (0.016)

74.3 ± 5.4 (0.016)

74.7 ± 6.2 (0.016)

Borg dyspnoea index

3.6 ± 1.4

2.3 ± 1.2b (0.063)

2.8 ± 1.5c (0.250)

3.2 ± 1.2b (1.000)

2.1 ± 1.2 (0.016)

2.9 ± 1.8 (0.313)

3.7 ± 2.9 (1.000)

2.4 ± 1.1 (0.250)

  1. SBP: systolic blood pressure; DBP: diastolic blood pressure; 6MWT: 6-minute walk test; SaO2: transcutaneous arterial oxygen saturation; SpO2: peak exercise transcutaneous arterial oxygen saturation.
  2. aWilcoxon signed-rank test (two-sided) on change from baseline statistically significant (p < 0.05).
  3. bn = 6 due to missing data.
  4. cn = 5 due to missing data.